An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

David Merrill, MD, PhD, is a psychiatrist at Providence Saint John's Health Center in Santa Monica, CA, and Singleton Endowed ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Esketamine, the ketamine-derived nasal spray sold under the brand name Spravato (esketamine), is indicated for patients with treatment-resistant depression. In October 2023, the FDA warned about ...

Ketamine has long been seen as a potential ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which ...

They also note that the oral tablets would be less prone to abuse and diversion than other ketamine formulations. They could also be cheaper, given that Spravato's US list price in the US is $590 ...